
global leader diagnost breast
imag surgic product focu women
health also sell medic aesthet
diagnost tool
knock door mid-single-digit
growth reiter hold rais pt
gradual execut cours year breast health
molecular diagnost busi pace growth off-set slower growth
declin segment look greater evid find solut
declin gross margin need time get confid cynosur
bottom nevertheless near mid-single-digit growth effect capit alloc
buyback tuck-in deal warm us stock deliv
top-lin beat cent bottom-lin beat rais fy top- bottom-lin guid
said rais revenu less beat fx headwind
one factor consist trend set low bar next report quarter
essenti rais underli baselin guid reiter hold pt
beat rev rep fxn exceed our/street
adj ep beat led modest beat across
divis compar model deliv beat diagnost beat
medic aesthet beat breast beat gyn/surg
beat skelet health adj om line
gross margin continu declin adj gm y/i miss
due on-going product mix stronger us higher servic cost china tariff
unclear us gross margin declin turn corner
breast remain bright spot breast rev
match street led growth us breast health off-set ou fxn
newer acquisit faxitron ad rev
addit help smartcurv paddl breast stabil system
perform dimens estim place geniu
unit us convert ib
cyno beat move division head diagnost cynosur rev
continu declin rev y/i beat our/street
saw growth skin off-set declin mona lisa touch bodi move
newer division head kevin thornal medic aesthet run diagnost
replac former dx presid tom west left becom ceo
intersect ent market cap replac mr thornal erik anderson
promot role vice-president sale cynosur manag indic new cyno
spokesperson brook shield see posit earli impact
guid rais revenue guid rep
fxn rep fxn adj ep
guid street out-
quarter rev rep prior
adj ep vs our/street prior
us pleas host cfo karleen oberton vice-president investor relat
mike watt next week annual canaccord genuiti growth confer
boston wednesday august pleas contact us detail
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
rais pt initi estim pt roll forward
multipl newli initi adj ep estim formerli pt
use multipl adj ep estim initi
revenu estim y/i report adj ep estim
growth segment make formal comment prepar
remark call regard segment growth outlook howev
compani track ahead goal breast health molecular diagnost
track goal cynosur previous indic formal
comment expect gener low- mid-single-digit revenu growth
segment except breast health segment target
mid-single-digit growth like breast health hit high singl digit
year molecular diagnost track achiev impress double-digit
growth year expect molecular diagnost remain strong given
razor/razorblad model industry-lead panther instrument unclear
cynosur might benefit look easi comp though
note compani easi comp year well still declin
fda warn letter mona lisa touch help manag indic
see solid contribut great season veteran small percentag
sale peopl previous work cynosur retain
major rep left base understand
hold unchang target price august
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price august
diagnost tool
hold unchang target price august
diagnost tool
